Intervention Review

You have free access to this content

Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma

  1. Khadra Galaal1,*,
  2. Esther van der Heijden2,
  3. Keith Godfrey3,
  4. Raj Naik4,
  5. Ali Kucukmetin3,
  6. Andrew Bryant5,
  7. Nagindra Das1,
  8. Alberto D Lopes1

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 22 JAN 2013

DOI: 10.1002/14651858.CD006812.pub3


How to Cite

Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A, Das N, Lopes AD. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD006812. DOI: 10.1002/14651858.CD006812.pub3.

Author Information

  1. 1

    Princess Alexandra Wing, Royal Cornwall Hospital, Gynaecological Oncology, Truro, UK

  2. 2

    Radboud University Nijmegen Medical Centre, Department of Gynaecology and Obstetrics, Nijmegen, Netherlands

  3. 3

    Northern Gynaecological Oncology Centre, Gynaecological Oncology, Gateshead, Tyne & Wear, UK

  4. 4

    Northern Gynaecological Oncology Centre, Gateshead, Tyne and Wear, UK

  5. 5

    Newcastle University, Institute of Health & Society, Newcastle upon Tyne, UK

*Khadra Galaal, Gynaecological Oncology, Princess Alexandra Wing, Royal Cornwall Hospital, Truro, TR1 3LJ, UK. k.galaal@nhs.net. khadragalaal@yahoo.co.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Homesley 2007 {published and unpublished data}
  • Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology Feb 10 2007;25(5):526-31.
Sutton 2000 {published data only}
  • Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecologic Oncology 2000;79(2):147-53.
Wolfson 2007 {published and unpublished data}
  • Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic Oncology 2007;107(2):177-85.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Asbury 1998 {published data only}
  • Asbury R, Blessing JA, Podczaski E, Ball H. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. American Journal of Clinical Oncology 1998;21(3):306-7.
Currie 1996 {published data only}
  • Currie JL, Blessing JA, McGehee R, Soper JT, Berman M. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 1996;61(1):94-6.
Curtin 2001 {published data only}
Fowler 2002 {published data only}
  • Fowler JM, Blessing JA, Burger RA, Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 2002;85(2):311-4.
Miller 2005 {published data only}
  • Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecologic Oncology 2005;98(2):217-21.
Perez 1979 {published data only}
Powell 2010 {published data only}
  • Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, et al. A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a GynecologicOncology Group Study. Journal of Clinical Oncolcogy 2010;28(16):2727-31.
Ramondetta 2003 {published data only}
  • Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets.[see comment]. Gynecologic Oncology 2003 Sep;90(3):529-36.
Resnik 1995 {published data only}
  • Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus. Gynecologic Oncology 1995;56(3):370-5.
Sutton 1989 {published data only}
  • Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). American Journal of Obstetrics and Gynecology 1989;161(2):309-12.
Sutton 2005 {published data only}
  • Sutton G, Kauderer J, Carsonc LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resectedstage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus:a Gynecologic Oncology Group study. Gynecologic Oncology 2005;96(3):630–4.
Toyoshima 2004 {published data only}
  • Toyoshima M, Akahira JI, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecologic Oncology 2004;94(3):774-8.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Arrastia 1997
Barwick 1979
Brooks 2004
Bucher 1997
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
Callister 2004
  • Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. International Journal of Radiation Oncology Biology Physics 2004;58(3):786-96.
Chi 1997
  • Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. [Review] [21 refs]. Gynecologic Oncology 1997 Jun;65(3):493-8.
CTCAE 2006
  • CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
Deeks 2001
  • Deeks JJ, Altman DG, Bradburn MJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
DerSimonian 1986
El Nashar 2011
FIGO 2009
Gadducci 2002
  • Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Cosio S, et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. European Journal of Gynaecological Oncology 2002;23(4):295-9.
Galaal 2009
  • Galaal K, Kew FM, Tam KF, Lopes AD, Meirovitz M, Naik R, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. European Journal of Obstetrics, Gynecology and Reproductive Bbiology 2009;143(2):88-92.
Harlow 1986
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org, [updated March 2011].
Le 2001
Major 1993
McCluggage 2002
Menczer 2005
  • Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecologic Oncology 2005;97(1):166-70.
Olah 1992
Omura 1983
  • Omura GA, Blessing JA, Major F, Silverberg S. A. randomised trial of adriamycin versus no adjuvant chemotherapy in stage I and stage II uterine sarcomas. Proceedings of the American Society of Clinical Oncology. 1983; Vol. C-580:149.
Parmer 1998
Sartori 1997
Spanos 1986
Szukala 1999
Thigpen 2004
  • Thigpen JT, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study. Gynecologic Oncology 2004;93(2):336-9.
Van Rijswijk 1994
  • Van Rijswijk REN, Tognon G, Burger CW, Baak JP, Kenemans P, Vermorken JB. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. International Journal of Gynecological Cancer 1994;4(1):52-60.
Young 1981
  • Young JL, Percy CL, Asire AJ, Berg JW, Cusano MM, Gloeckler LA, et al. Cancer incidence and mortality in the United States, 1973-77. National Cancer Institute Monograph 1981;57:1-187.
Zelmanowicz 1998
  • Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecologic Oncology 1998;69( 3):253-7.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Galaal 2011